UCB to acquire maker of antibody treatments for autoimmune diseases
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UCB to acquire Candid Therapeutics for $2.2 bn, adding a bispecific antibody platform that redirects T cells to BCMA on B cells.
- Latus Bio raised $42 million to advance gene‑therapy candidates for Batten disease and a novel approach to Huntington’s disease targeting MSH3.
- U.S. immigration delays are prompting international scientists to stay abroad, risking a long‑term brain drain that could erode the U.S. research edge.
Why it matters: UCB secures a $2.2 bn asset, boosting its market position; the U.S. research sector loses talent as visa delays push scientists abroad, potentially slowing drug discovery and economic growth.
Ask SkimNews
